Skip to main content

What investors need to know about Pfizer’s latest downgrade

The company's pipeline, though promising, is still too premature to make up for the looming drop in COVID-19 franchise revenue.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.